sameAs
P3355
Pre-clinical characterization of Dacomitinib (PF-00299804), an irreversible pan-ErbB inhibitor, combined with ionizing radiation for head and neck squamous cell carcinoma.Wasted research when systematic reviews fail to provide a complete and up-to-date evidence synthesis: the example of lung cancer.Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.Current Role of Dacomitinib in Head and Neck Cancer.Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitroDacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study.Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers.Investigation of dacomitinib on reducing cell necrosis and enhancing cell apoptosis in C6 glioma rat model by MRI
P921
Q25100112-D309C65B-D696-453A-9426-BFBACC0F4CC6Q27908387-1036064F-CAF8-4D46-8080-BC713E1CA86AQ28370972-778F638B-7922-4F40-9E64-9CB3FFAF449FQ28370972-89444978-73F5-45CB-AE27-6BA4AF376F14Q28370979-F6CF31A1-D5FD-4F54-9807-54A3E5092829Q28371378-F83DEEB7-7E2F-4566-B7EB-391E6410B8F8Q28371689-0BFF40DC-C785-4B8D-BFD8-526494B826F2Q28371691-2CF8605C-17D7-49C6-B6DD-3AFCE78E4A05Q28371692-129D5A86-C783-4C0E-A912-BA2EFEB3ABA0Q28381469-4010259B-0DE4-4A26-AA16-75986DDD56A7Q28445020-861A6303-813E-481F-AD20-4D10A9481A6FQ28531504-A50098F9-BE5C-42EE-9EC8-FA290F72E10A
P3354
Q35172674-67B1F91E-AAE5-4B36-B750-0886DA48F5D1Q35899612-1EE7F371-A701-45F8-BF42-204C4C670E4CQ37659109-A71B7943-84B3-414B-9EAF-A3FC9B095C32Q38382659-9187BEE6-046B-48DF-A865-E49B23FFA366Q38806115-4C0E3A2C-84B3-4617-A934-E70A6FB7CE78Q38854643-7D44B671-4D5F-4C9E-8FFE-1D1C5D74CEABQ38911022-6492FFE2-A991-4340-8393-AAC3DCAD2D1CQ39320168-ADDB61CB-9313-492A-9E46-3637A9B94394Q46602504-AE0988D4-A66F-40B7-9CD7-B1382C2E9870Q51299907-2358767E-A8F9-4416-ABB6-4FF61619F31BQ64055547-24C11D67-02F9-42D9-85BE-CD660E1F4A05
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Dacomitinib
@vi
dacomitinib
@en
ダコミチニブ
@ja
達科米替尼
@zh
type
label
Dacomitinib
@vi
dacomitinib
@en
ダコミチニブ
@ja
達科米替尼
@zh
altLabel
PF 00299804-03
@en
PF-00299804
@en
PF-00299804-03
@en
dacomitinib anhydrous
@en
prefLabel
Dacomitinib
@vi
dacomitinib
@en
ダコミチニブ
@ja
達科米替尼
@zh
P129
P592
P6366
P661
P662
P665
P683
P117
P129
P1579
P2017
COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)/C=C/CN4CCCCC4
P2067
P2275
dacomitinib
@en
P231
1110813-31-4
P233
COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)C=CCN4CCCCC4
P234
1S/C24H25ClFN5O2/c1-33-22-14-2 ...... H3,(H,30,32)(H,27,28,29)/b6-5+
P235
LVXJQMNHJWSHET-AATRIKPKSA-N
P267
P274
C₂₄H₂₅ClFN₅O₂